MX2021006329A - Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso. - Google Patents
Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso.Info
- Publication number
- MX2021006329A MX2021006329A MX2021006329A MX2021006329A MX2021006329A MX 2021006329 A MX2021006329 A MX 2021006329A MX 2021006329 A MX2021006329 A MX 2021006329A MX 2021006329 A MX2021006329 A MX 2021006329A MX 2021006329 A MX2021006329 A MX 2021006329A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- substituted amino
- receptor antagonists
- adenosine receptor
- quinazoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En su gran cantidad de formas de realización, la presente invención proporciona determinados compuestos de amino triazolo quinazolina 9-sustituidos de la Fórmula estructural (I): (ver Fórmula) (I), y sales de aquellos farmacéuticamente aceptables, en donde el anillo A, R1 y R2 son como se definen en la presente, composiciones farmacéuticas que comprenden uno o más de estos compuestos (solos o en combinación con uno o más agentes terapéuticamente activos diferentes), y métodos para su preparación y uso, solos o en combinación con otros agentes terapéuticos, como antagonistas de receptores A2a y/o A2b, y en el tratamiento de diversas enfermedades, afecciones o trastornos que están mediadas, al menos en parte, por el receptor de adenosina A2a y/o el receptor de adenosina A2b.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774077P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/063136 WO2020112700A1 (en) | 2018-11-30 | 2019-11-26 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006329A true MX2021006329A (es) | 2021-08-11 |
Family
ID=69005832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006329A MX2021006329A (es) | 2018-11-30 | 2019-11-26 | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso. |
Country Status (25)
Country | Link |
---|---|
US (1) | US11312719B2 (es) |
EP (1) | EP3886988A1 (es) |
JP (1) | JP7241871B2 (es) |
KR (1) | KR102653800B1 (es) |
CN (1) | CN113329791A (es) |
AR (1) | AR117164A1 (es) |
AU (1) | AU2019385905B2 (es) |
BR (1) | BR112021010427B1 (es) |
CA (1) | CA3120862C (es) |
CL (1) | CL2021001406A1 (es) |
CO (1) | CO2021006888A2 (es) |
CR (1) | CR20210271A (es) |
DO (1) | DOP2021000104A (es) |
EA (1) | EA202191498A1 (es) |
EC (1) | ECSP21036982A (es) |
IL (1) | IL283334A (es) |
JO (2) | JOP20210117A1 (es) |
MA (1) | MA54298A (es) |
MX (1) | MX2021006329A (es) |
NI (1) | NI202100043A (es) |
PE (1) | PE20211768A1 (es) |
PH (1) | PH12021551196A1 (es) |
SG (1) | SG11202105180PA (es) |
TW (1) | TW202039496A (es) |
WO (1) | WO2020112700A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
EP3787627A4 (en) | 2018-05-02 | 2021-12-01 | Navire Pharma, Inc. | SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11 |
SI3833670T1 (sl) | 2018-08-10 | 2024-07-31 | Navire Pharma, Inc. | Derivati spojine 6-(4-amino-3-metil-2-oksa-8-azaspiro(4.5)dekan-8-il)-3-(2,3-diklorofenil -2-metilpirimidin-4(3H)-on in sorodne spojine kot zaviralci PTPN11 (SHP2)za zdravljenje raka |
BR112021010273A2 (pt) * | 2018-11-30 | 2021-08-17 | Merck Sharp & Dohme Corp. | derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso |
WO2023158626A1 (en) * | 2022-02-16 | 2023-08-24 | Merck Sharp & Dohme Llc | Adenosine receptor antagonists, pharmaceutical compositions and their use thereof |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024118460A1 (en) * | 2022-11-29 | 2024-06-06 | Merck Sharp & Dohme Llc | Adenosine a2a and a2b receptor antagonists, pharmaceutical compositions and use thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957766A (en) | 1970-06-19 | 1976-05-18 | Boehringer Mannheim G.M.B.H. | Novel nitrofuran compounds and pharmaceutical compositions |
DE2109577A1 (de) | 1971-03-01 | 1972-09-14 | Boehringer Mannheim Gmbh | Antimikrobiell wirksame Nitrofuran Derivate und Verfahren zur Herstellung derselben |
US4713383A (en) | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
GB9524395D0 (en) | 1995-11-29 | 1996-01-31 | Nickerson Biocem Ltd | Promoters |
US6759759B2 (en) | 2000-08-29 | 2004-07-06 | Tamagawa Seiki Kabushiki Kaisha | Rotary contactless connector and non-rotary contactless connector |
JP4545437B2 (ja) | 2001-10-15 | 2010-09-15 | シェーリング コーポレイション | アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン |
TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
WO2003048165A1 (en) | 2001-11-30 | 2003-06-12 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
CA2500228A1 (en) | 2002-09-24 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]-triazolo[1,5-c]pyrimidine derivative |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトpd−1に対し特異性を有する物質 |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
SI1678182T1 (sl) | 2003-10-28 | 2007-06-30 | Schering Corp | Postopek priprave substituiranih 5-amino-pirazolo- (4,3-e)-1,2,4-triazolo(1,5-)pirimidinov |
TW200538118A (en) | 2004-04-21 | 2005-12-01 | Schering Corp | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
US7472383B2 (en) | 2004-08-13 | 2008-12-30 | Sun Microsystems, Inc. | System and method for providing exceptional flow control in protected code through memory layers |
DE602005014891D1 (de) | 2004-12-21 | 2009-07-23 | Schering Corp | PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
JP2009508871A (ja) | 2005-09-19 | 2009-03-05 | シェーリング コーポレイション | アデノシンA2a受容体アンタゴニストとしての2−ヘテロアリール−ピラゾロ−[4,3−e]−1,2,4−トリアゾロ−[1,5−c]−ピリミジン |
MX2009000104A (es) | 2006-06-26 | 2009-01-23 | Schering Corp | Antagonistas del receptor de adenosina a2a. |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
PE20091101A1 (es) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO |
JP2011514350A (ja) | 2008-03-04 | 2011-05-06 | シェーリング コーポレイション | アデノシンA2a受容体アンタゴニストとして使用するためのアミノ−キノキサリンおよびアミノ−キノリン化合物 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
CN104740610A (zh) | 2008-08-25 | 2015-07-01 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
US9495379B2 (en) | 2012-10-08 | 2016-11-15 | Veritas Technologies Llc | Locality aware, two-level fingerprint caching |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
BR112017010261A2 (pt) | 2014-11-18 | 2018-02-06 | Merck Sharp & Dohme Corp. | composto, composição farmacêutica, e, método de tratamento para tratar distúrbios do sistema nervoso central (cns). |
WO2016089796A1 (en) | 2014-12-04 | 2016-06-09 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
US10688082B2 (en) | 2015-06-11 | 2020-06-23 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
WO2016209787A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Sustained release formulation and tablets prepared therefrom |
WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
BR112019014193A2 (pt) * | 2017-01-20 | 2020-03-17 | Arcus Biosciences, Inc. | Azolopirimidina para o tratamento de distúrbios relacionados com câncer |
EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
EP3883575A4 (en) | 2018-11-20 | 2022-06-15 | Merck Sharp & Dohme Corp. | SUBSTITUTE AMINO-TRIAZOLOPYRIMIDINE AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
US20220040184A1 (en) | 2018-11-20 | 2022-02-10 | Merck Sharp Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
BR112021010273A2 (pt) | 2018-11-30 | 2021-08-17 | Merck Sharp & Dohme Corp. | derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso |
-
2019
- 2019-11-26 CA CA3120862A patent/CA3120862C/en active Active
- 2019-11-26 EA EA202191498A patent/EA202191498A1/ru unknown
- 2019-11-26 JO JOP/2021/0117A patent/JOP20210117A1/ar unknown
- 2019-11-26 CR CR20210271A patent/CR20210271A/es unknown
- 2019-11-26 EP EP19827893.9A patent/EP3886988A1/en active Pending
- 2019-11-26 US US16/695,367 patent/US11312719B2/en active Active
- 2019-11-26 AU AU2019385905A patent/AU2019385905B2/en active Active
- 2019-11-26 CN CN201980090487.8A patent/CN113329791A/zh active Pending
- 2019-11-26 BR BR112021010427-5A patent/BR112021010427B1/pt active IP Right Grant
- 2019-11-26 TW TW108142874A patent/TW202039496A/zh unknown
- 2019-11-26 WO PCT/US2019/063136 patent/WO2020112700A1/en active Application Filing
- 2019-11-26 JP JP2021530114A patent/JP7241871B2/ja active Active
- 2019-11-26 MX MX2021006329A patent/MX2021006329A/es unknown
- 2019-11-26 AR ARP190103450A patent/AR117164A1/es unknown
- 2019-11-26 JO JOP/2021/0116A patent/JOP20210116A1/ar unknown
- 2019-11-26 KR KR1020217019802A patent/KR102653800B1/ko active IP Right Grant
- 2019-11-26 MA MA054298A patent/MA54298A/fr unknown
- 2019-11-26 PE PE2021000757A patent/PE20211768A1/es unknown
- 2019-11-26 SG SG11202105180PA patent/SG11202105180PA/en unknown
-
2021
- 2021-05-20 IL IL283334A patent/IL283334A/en unknown
- 2021-05-24 NI NI202100043A patent/NI202100043A/es unknown
- 2021-05-25 PH PH12021551196A patent/PH12021551196A1/en unknown
- 2021-05-25 EC ECSENADI202136982A patent/ECSP21036982A/es unknown
- 2021-05-26 CO CONC2021/0006888A patent/CO2021006888A2/es unknown
- 2021-05-27 CL CL2021001406A patent/CL2021001406A1/es unknown
- 2021-05-27 DO DO2021000104A patent/DOP2021000104A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20211768A1 (es) | 2021-09-07 |
JOP20210116A1 (ar) | 2023-01-30 |
TW202039496A (zh) | 2020-11-01 |
JOP20210117A1 (ar) | 2023-01-30 |
EP3886988A1 (en) | 2021-10-06 |
CO2021006888A2 (es) | 2021-06-10 |
SG11202105180PA (en) | 2021-06-29 |
ECSP21036982A (es) | 2021-06-30 |
US20220220117A1 (en) | 2022-07-14 |
MA54298A (fr) | 2022-03-09 |
KR102653800B1 (ko) | 2024-04-01 |
JP2022511441A (ja) | 2022-01-31 |
DOP2021000104A (es) | 2021-07-30 |
NI202100043A (es) | 2021-08-13 |
AR117164A1 (es) | 2021-07-14 |
EA202191498A1 (ru) | 2021-08-20 |
CA3120862C (en) | 2024-05-07 |
CL2021001406A1 (es) | 2021-11-12 |
US11312719B2 (en) | 2022-04-26 |
US20210107904A1 (en) | 2021-04-15 |
CR20210271A (es) | 2021-07-14 |
BR112021010427A2 (pt) | 2021-08-17 |
BR112021010427B1 (pt) | 2022-09-27 |
PH12021551196A1 (en) | 2021-11-29 |
AU2019385905B2 (en) | 2023-01-12 |
CN113329791A (zh) | 2021-08-31 |
KR20210096184A (ko) | 2021-08-04 |
JP7241871B2 (ja) | 2023-03-17 |
AU2019385905A1 (en) | 2021-06-03 |
WO2020112700A1 (en) | 2020-06-04 |
IL283334A (en) | 2021-07-29 |
CA3120862A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
CL2019003650A1 (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios. | |
MX2018003186A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer. | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
AR074240A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci | |
PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
CR20210456A (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
MX2022004121A (es) | Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor. | |
TW200640904A (en) | Quinazoline derivatives | |
MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
MX2021004885A (es) | Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor. | |
MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. |